A live cell NanoBRET binding assay allows the study of ligand-binding kinetics to the adenosine A3 receptor

Monica Bouzo-Lorenzo,Leigh A. Stoddart,Lizi Xia,Adriaan P. IJzerman,Laura H. Heitman,Stephen J. Briddon,Stephen J. Hill
DOI: https://doi.org/10.1007/s11302-019-09650-9
2019-03-27
Purinergic Signalling
Abstract:There is a growing interest in understanding the binding kinetics of compounds that bind to G protein-coupled receptors prior to progressing a lead compound into clinical trials. The widely expressed adenosine A<sub>3</sub> receptor (A<sub>3</sub>AR) has been implicated in a range of diseases including immune conditions, and compounds that aim to selectively target this receptor are currently under development for arthritis. Kinetic studies at the A<sub>3</sub>AR have been performed using a radiolabelled antagonist, but due to the kinetics of this probe, they have been carried out at 10 °C in membrane preparations. In this study, we have developed a live cell NanoBRET ligand binding assay using fluorescent A<sub>3</sub>AR antagonists to measure kinetic parameters of labelled and unlabelled compounds at the A<sub>3</sub>AR at physiological temperatures. The kinetic profiles of four fluorescent antagonists were determined in kinetic association assays, and it was found that XAC-ser-tyr-X-BY630 had the longest residence time (RT = 288 ± 62 min) at the A<sub>3</sub>AR. The association and dissociation rate constants of three antagonists PSB-11, compound 5, and LUF7565 were also determined using two fluorescent ligands (XAC-ser-tyr-X-BY630 or AV039, RT = 6.8 ± 0.8 min) as the labelled probe and compared to those obtained using a radiolabelled antagonist ([<sup>3</sup>H]PSB-11, RT = 44.6 ± 3.9 min). There was close agreement in the kinetic parameters measured with AV039 and [<sup>3</sup>H]PSB-11 but significant differences to those obtained using XAC-<em>S</em>-ser-<em>S</em>-tyr-X-BY630. These data indicate that selecting a probe with the appropriate kinetics is important to accurately determine the kinetics of unlabelled ligands with markedly different kinetic profiles.
neurosciences
What problem does this paper attempt to address?